FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103506609> ?p ?o ?g. }

• W2103506609 endingPage "4075" @default.
• W2103506609 startingPage "4068" @default.
• W2103506609 abstract "Purpose Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen. Patients and Methods Eligibility criteria included histologically proven mRCC with measurable disease, failure of one prior cytokine regimen, and good performance status. Patients were randomly assigned to a sunitinib starting dose of 37.5 mg/d in the morning (AM) or evening (PM). RECIST-defined objective response rate (ORR) was the primary end point. Secondary end points included progression-free survival (PFS), overall survival (OS), adverse events (AEs), and quality-of-life measures. Results One hundred seven patients were randomly assigned to AM (n = 54) or PM (n = 53) dosing and on study for a median 8.3 months. Eighty-three patients discontinued, 65 due to disease progression and 16 because of AEs; two patients withdrew consent. Dosing was reduced to 25 mg/d in 46 patients (43%) due to grade 3/4 AEs. The most common grade 3 treatment-related AEs were asthenia/fatigue (16%), diarrhea (11%), hypertension (11%), hand-foot syndrome (9%), and anorexia (8%). ORR was 20% with a 7.2-month median response duration. Median PFS and OS were 8.2 and 19.8 months, respectively, at median follow-up of 26.4 months. Efficacy, tolerability, and quality-of-life results were similar between patients dosed in the AM or PM. Conclusion Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies." @default.
• W2103506609 created "2016-06-24" @default.
• W2103506609 creator A5006943528 @default.
• W2103506609 creator A5009101766 @default.
• W2103506609 creator A5009723460 @default.
• W2103506609 creator A5017835221 @default.
• W2103506609 creator A5019474260 @default.
• W2103506609 creator A5041575636 @default.
• W2103506609 creator A5046145687 @default.
• W2103506609 creator A5049672639 @default.
• W2103506609 creator A5059219836 @default.
• W2103506609 creator A5063926652 @default.
• W2103506609 creator A5066200247 @default.
• W2103506609 creator A5073852083 @default.
• W2103506609 date "2009-09-01" @default.
• W2103506609 modified "2023-10-03" @default.
• W2103506609 title "Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma" @default.
• W2103506609 cites W1587086507 @default.
• W2103506609 cites W1880480189 @default.
• W2103506609 cites W1942070062 @default.
• W2103506609 cites W1976689062 @default.
• W2103506609 cites W2015644147 @default.
• W2103506609 cites W2016757878 @default.
• W2103506609 cites W2020830322 @default.
• W2103506609 cites W2029245281 @default.
• W2103506609 cites W2030709723 @default.
• W2103506609 cites W2031614751 @default.
• W2103506609 cites W2038962823 @default.
• W2103506609 cites W2046507292 @default.
• W2103506609 cites W2077058055 @default.
• W2103506609 cites W2097415839 @default.
• W2103506609 cites W2097976367 @default.
• W2103506609 cites W2098136315 @default.
• W2103506609 cites W2102996502 @default.
• W2103506609 cites W2105677187 @default.
• W2103506609 cites W2106453307 @default.
• W2103506609 cites W2113416338 @default.
• W2103506609 cites W2129841021 @default.
• W2103506609 cites W2139248078 @default.
• W2103506609 cites W2139511378 @default.
• W2103506609 cites W2143782771 @default.
• W2103506609 cites W2149032069 @default.
• W2103506609 cites W2150452646 @default.
• W2103506609 cites W2156408558 @default.
• W2103506609 cites W2171469612 @default.
• W2103506609 cites W2210929914 @default.
• W2103506609 cites W2227340362 @default.
• W2103506609 cites W2275552236 @default.
• W2103506609 cites W2334694951 @default.
• W2103506609 cites W2473786944 @default.
• W2103506609 cites W2768600953 @default.
• W2103506609 cites W4293241248 @default.
• W2103506609 doi "https://doi.org/10.1200/jco.2008.20.5476" @default.
• W2103506609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19652072" @default.
• W2103506609 hasPublicationYear "2009" @default.
• W2103506609 type Work @default.
• W2103506609 sameAs 2103506609 @default.
• W2103506609 citedByCount "194" @default.
• W2103506609 countsByYear W21035066092012 @default.
• W2103506609 countsByYear W21035066092013 @default.
• W2103506609 countsByYear W21035066092014 @default.
• W2103506609 countsByYear W21035066092015 @default.
• W2103506609 countsByYear W21035066092016 @default.
• W2103506609 countsByYear W21035066092017 @default.
• W2103506609 countsByYear W21035066092018 @default.
• W2103506609 countsByYear W21035066092019 @default.
• W2103506609 countsByYear W21035066092020 @default.
• W2103506609 countsByYear W21035066092021 @default.
• W2103506609 countsByYear W21035066092022 @default.
• W2103506609 countsByYear W21035066092023 @default.
• W2103506609 crossrefType "journal-article" @default.
• W2103506609 hasAuthorship W2103506609A5006943528 @default.
• W2103506609 hasAuthorship W2103506609A5009101766 @default.
• W2103506609 hasAuthorship W2103506609A5009723460 @default.
• W2103506609 hasAuthorship W2103506609A5017835221 @default.
• W2103506609 hasAuthorship W2103506609A5019474260 @default.
• W2103506609 hasAuthorship W2103506609A5041575636 @default.
• W2103506609 hasAuthorship W2103506609A5046145687 @default.
• W2103506609 hasAuthorship W2103506609A5049672639 @default.
• W2103506609 hasAuthorship W2103506609A5059219836 @default.
• W2103506609 hasAuthorship W2103506609A5063926652 @default.
• W2103506609 hasAuthorship W2103506609A5066200247 @default.
• W2103506609 hasAuthorship W2103506609A5073852083 @default.
• W2103506609 hasConcept C126322002 @default.
• W2103506609 hasConcept C141071460 @default.
• W2103506609 hasConcept C197934379 @default.
• W2103506609 hasConcept C2777288759 @default.
• W2103506609 hasConcept C2777472916 @default.
• W2103506609 hasConcept C2778375690 @default.
• W2103506609 hasConcept C2779490328 @default.
• W2103506609 hasConcept C2781413609 @default.
• W2103506609 hasConcept C71924100 @default.
• W2103506609 hasConcept C90924648 @default.
• W2103506609 hasConceptScore W2103506609C126322002 @default.
• W2103506609 hasConceptScore W2103506609C141071460 @default.
• W2103506609 hasConceptScore W2103506609C197934379 @default.
• W2103506609 hasConceptScore W2103506609C2777288759 @default.
• W2103506609 hasConceptScore W2103506609C2777472916 @default.

• next